A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study)

Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii

“…Doripenem possesses a sulfamoyl-aminomethyl-pyrrolidinylthio group in its side chain, which improves its activity against nonfermentative bacilli (Jones et al 2004;Fritsche et al 2005). Doripenem has been approved for the treatment of a wide variety of infections such as nosocomial pneumonia, complicated urinary tract and intra-abdominal infections in the United States, the European Union and in the East-Asian countries (Ikawa et al 2008;Samtani et al 2010;Harada et al 2013;Mustafa et al 2014;Matsuo et al 2015). Assessment of the susceptibilities of Gram-negative bacteria to three carbapenems including imipenem, meropenem, and doripenem was conducted through the COMParative Activity of Carbapenem Testing (COM-PACT) study in Europe, Asia-Pacific and the Middle East regions Lee et al 2011;Nordmann et al 2011;Kiratisin et al 2012;Leblebicioglu et al 2012;Valenza et al 2012).…”

Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia

“…By contrast with the study by Kollef and colleagues, 2 which was unable to show non-inferiority for doripenem, the other two studies 3,4 compared doripenem with comparators over a similar treatment duration and reported noninferiority for doripenem. Doripenem was most commonly used for treating pneumonia in a surveillance study, 5 and a meta-analysis up to April, 2019, 6 showed that doripenem was non-inferior to comparators in the treatment of nosocomial pneumonia and ventilator-associated pneumonia. Therefore, we wonder whether doripenem can achieve noninferior efficacy if it can be used for the same duration as the comparator.…”

“…4 This finding led to a third clinical trial with doripenem in patients with confirmed ventilatorassociated pneumonia; however, the trial was stopped early because of higher mortality and lower clinical response in the doripenem group. 5 Mortality was predominantly driven by pseudomonas infections, and outcomes were worse in patients with augmented renal clearance. As a result, doripenem was not approved for hospital-acquired pneumonia or ventilator-associated pneumonia in several countries (including the USA), whereas in others (including the European Economic Area) it was approved only for hospital-acquired pneumonia.…”

Antimicrobial Therapy of Patients With Fan-Associated Pneumonia: Focus on Dopirenem

“…Эффект был наилуч-шим при антраабдоминальных инфекциях (93,9%) и наи-худшим при ВАП (79,6%). Смертность от разных причин составила 22,7% [27].…”